Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-813160 |
Synonyms | |
Therapy Description |
BMS-813160 inhibits both CCR2 and CCR5, potentially modulating immune response (PMID: 21936726). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-813160 | BMS 813160|BMS813160 | BMS-813160 inhibits both CCR2 and CCR5, potentially modulating immune response (PMID: 21936726). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03184870 | Phase Ib/II | BMS-813160 + Fluorouracil + Irinotecan + Leucovorin BMS-813160 + Nivolumab BMS-813160 + Gemcitabine + Nab-paclitaxel BMS-813160 | A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | ESP | DEU | CAN | BEL | AUS | 0 |